

INDEX

BIO-SCIENCE LAW REVIEW

VOLUME 15

CONTENTS

Subject Index	i
Countries and Institutions	ii
Contributors	iii
Contributions	iv
Case List	iv

Subject Index

BIOLOGICS

Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia (Case Comment) 2 73

BIOSIMILARS

Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia (Case Comment) 2 73

COMPETITION

Pharmaceutical products

GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements (Case Comment) 2 68

COSMETIC PRODUCTS

Nagoya Protocol

Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by *Sophora Japonica* (Article) 4 142

DATA EXCLUSIVITY

Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia (Case Comment) 2 73

GM INSECTS

What's all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects (Case Comment) 2 76

INTERNATIONAL RELATIONS

Brexit and life sciences: product authorisation and exclusivity rights (Article) 6 215

MEDICAL TREATMENTS

Patentability of medical treatments (Article) 6 224

MEDICINAL PRODUCTS

Latest news on medicinal product SPCs in Europe (Article) 1 18
 Nexus between inspection and enforcement: *R (Roche Registration Ltd) v Secretary of State for Health* (Case Comment) 2 63
 Promoting the off-label use of medicines: where to draw the line? (Article) 1 3

NAGOYA PROTOCOL

EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources (Article) 3 83
 Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by *Sophora Japonica* (Article) 4 142

NANOMATERIALS

Regulation

Nanomaterials in the EU regulatory framework on chemical products (Article) 2 49

PATENTS

Competition

Genentech: the Court of Justice of the EU rejects a competition law defence in a patent royalty action (Case Comment) 4 165

Declaratory relief

Declaratory relief in the English Patents Court (Case Comment) 3 123

Diagnostic method

Diagnostic method claims in Canada (Article) 1 12

Experts

Experts in the Unified Patent Court (Article) 2 44

Patentability

Henry Carr J jabs patentability in Men B case (Article) 4 131
 Isolated nucleic acid sequences no longer patentable in Australia: *D'Arcy v Myriad Genetics Inc* (Case Comment) 1 25
 Patentability of medical treatments (Article) 6 224

Pharmaceutical products

Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119

Plant breeding

EU Commission notice on plants from essentially biological processes: problem solved? (Article) 6 231
 Generating value in the soybean chain through royalty collection: an international study (Articles) 5 171

Plausibility

Blurred lines? Patents and plausibility (Article) 2 39

Public interest

Compulsory licences and patent revocations: does public interest rule the roost? (Article) 4 148

Supplementary Protection Certificates

Calculation of SPC duration: Case C-471/14 *Seattle Genetics* (Case Comment) 1 31
 Latest case on SPCs: the CJEU rules in favour of chaos (Case Comment) 6 248
 Latest news on medicinal product SPCs in Europe (Article) 1 18

Unified Patent Court

UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

PHARMACEUTICAL PRODUCTS

Antibiotics

Antimicrobial resistance: a brief review of the O'Neill report (Case Comment) 4 162
UN leads the way on antimicrobial resistance (Case Comment) 6 252

Clinical trials

Regulatory guidance: the importance of clarity
R (Richmond Pharmacology Ltd) v Health Research Authority (Case Comment) 4 158

Competition

GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements (Case Comment) 2 68

Injunctions

Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111

PLANT BREEDING

Royalties

Generating value in the soybean chain through royalty collection: an international study (Articles) 5 171

TRADE SECRETS

EU Trade Secrets Directive: a case of form over substance (Article) 6 239

Countries and Institutions

ARGENTINA

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 176

AUSTRALIA

Data exclusivity

Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia (Case Comment) 2 73

Patents

Isolated nucleic acid sequences no longer patentable in Australia: *D'Arcy v Myriad Genetics Inc* (Case Comment) 1 25
Patentability of medical treatments (Article) 6 224

BELGIUM

Medicinal products

Promoting the off-label use of medicines: where to draw the line? (Article) 1 3

BRAZIL

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 179

CANADA

Patents

Diagnostic method claims in Canada (Article) 1 12

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 182

COURT OF JUSTICE OF THE EUROPEAN UNION

Patents

Calculation of SPC duration: Case C-471/14 *Seattle Genetics* (Case Comment) 1 31
Genentech: the Court of Justice of the EU rejects a competition law defence in a patent royalty action (Case Comment) 4 165
Latest case on SPCs: the CJEU rules in favour of chaos (Case Comment) 6 248

EUROPEAN COMMISSION

Patents

EU Commission notice on plants from essentially biological processes: problem solved? (Article) 6 231

EUROPEAN UNION

Cosmetic products

Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by *Sophora Japonica* (Article) 4 142

Medicinal products

Promoting the off-label use of medicines: where to draw the line? (Article) 1 3

Nagoya Protocol

EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources (Article) 3 83
Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by *Sophora Japonica* (Article) 4 142

Nanomaterials

Nanomaterials in the EU regulatory framework on chemical products (Article) 2 49

Patents

Experts in the Unified Patent Court (Article) 2 44
Latest news on medicinal product SPCs in Europe (Article) 1 18
UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

Trade secrets

EU Trade Secrets Directive: a case of form over substance (Article) 6 239

FRANCE

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 184

GERMANY

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 187

HUNGARY

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 189

INDIA

Patents

Compulsory licences and patent revocations: does public interest rule the roost? (Article) 4 148

ITALY**Plant breeding**

Generating value in the soybean chain through royalty collection: an international study (Article) 5 192

PARAGUAY**Plant breeding**

Generating value in the soybean chain through royalty collection: an international study (Article) 5 192

SERBIA**Plant breeding**

Generating value in the soybean chain through royalty collection: an international study (Article) 5 197

SOUTH AFRICA**Plant breeding**

Generating value in the soybean chain through royalty collection: an international study (Article) 5 199

UNIFIED PATENT COURT

Experts in the Unified Patent Court (Article) 2 44
UPC Rules of Procedure are agreed. What do they say? (Article) 1 8

UNITED KINGDOM**Competition**

GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements (Case Comment) 2 68

GM insects

What's all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects (Case Comment) 2 76

International relations

Brexit and life sciences: product authorisation and exclusivity rights (Article) 6 215

Medicinal products

Nexus between inspection and enforcement:
R (Roche Registration Ltd) v Secretary of State for Health (Case Comment) 2 63

Patents

Blurred lines? Patents and plausibility (Article) 2 39
Declaratory relief in the English Patents Court (Case Comment) 3 123
Henry Carr J jabs patentability in Men B case (Article) 4 131
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Patentability of medical treatments (Article) 6 224
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119

Pharmaceutical products

Antimicrobial resistance: a brief review of the O'Neill report (Case Comment) 4 162
Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC (Article) 3 111
Regeneron Pharmaceuticals v Kymab and Novo Nordisk (Case Comment) 3 119
Regulatory guidance: the importance of clarity
R (Richmond Pharmacology Ltd) v Health Research Authority (Case Comment) 4 158

UNITED NATIONS**Pharmaceutical products**

UN leads the way on antimicrobial resistance (Case Comment) 6 252

UNITED STATES**Patents**

Patentability of medical treatments (Article) 6 224

Plant breeding

Generating value in the soybean chain through royalty collection: an international study (Article) 5 203

URUGUAY**Plant breeding**

Generating value in the soybean chain through royalty collection: an international study (Article) 5 204

Contributors

Balešević-Tubić, Svetlana (Article) 5 197
Belzer, Bill (Article) 5 203
Bergadá, Pablo (Article) 5 176
Blakeney, Michael (Article) 6 224
Broderick, Dervla (Case Comment) 2 68
Carter, Ailsa (Article) 4 131
Churi, Asawari (Case Comments) 4 162, 6 252
Cline, Helen (Case Comment) 2 76
Conti, Stefano (Article) 5 192
Cooper, John (Case Comment) 2 63
De Jong, Philippe (Article) 3 83
De la Soujeole, Antoine Alègre (Article) 5 184
De Pastors, Alice (Article) 1 18
Devitt, Crosby (Article) 5 182
England, Paul (Articles) 1 8, 2 44, 6 215; (Case Comment) 3 123
Enriquez, Roberto (Article) 5 176
Forwood, Genevra (Article) 1 3
Gerard, Bryan (Article) 5 203
Giannino, Michele (Case Comment) 4 165
Goldschagg, Eddie (Article) 5 199
Hull, John (Article) 6 239
Ing, Y. Lynn (Article) 1 12
Jackson, Stuart (Case Comment) 3 119
Killick, James (Article) 1 3; (Case Comment) 1 25
Kock, Michael A. (Article) 6 231
Mendizabal Frers, Juan F. (Article) 5 176
Morgan, Gareth (Case Comment) 1 31
Muyldermans, Dominic (Article) 3 83
Neuman, Teresa (Article) 5 182
Nickless, David (Article) 2 39
O'Connell, Kim (Case Comments) 1 25, 2 73
O'Sullivan, Nina (Article) 3 111
Ojeda G., María Estela (Article) 5 195
Payne, Andrew (Case Comment) 3 123
Polgár, Gábor (Article) 5 189
Ramanujan, Adarsh (Article) 4 148
Ramirez de la Piscina, Aratz (Article) 2 49
Rapela, Miguel A. (Article) 5 171, 176
Risso, Diego (Article) 5 204
Roberts, Tim (Book Review) 1 33
Rodrigues, José Américo Pierre (Article) 5 179
Rose, David (Article) 3 111
Royle, Matthew (Article) 6 215
Snodin, Mike (Case Comment) 6 248
Spies, Anna (Case Comment) 2 73
Van Vooren, Bart (Article) 4 142
Warburton, Chris (Case Comments) 2 63, 4 158
Whitehead, Brian (Case Comment) 3 119

Contributions

ARTICLES

- Blurred lines? Patents and plausibility *David Nickless* 2 39
- Brexit and life sciences: product authorisation and exclusivity rights *Paul England and Matthew Royle* 6 215
- Compulsory licences and patent revocations: does public interest rule the roost? *Adarsh Ramanujan* 4 148
- Diagnostic method claims in Canada *Y. Lynn Ing* 1 12
- EU Commission notice on plants from essentially biological processes: problem solved? *Michael A. Kock* 6 231
- EU regulatory framework for compliance with rules on access and benefit-sharing of genetic resources *Philippe de Jong and Dominic Muyldermans* 3 83
- EU Trade Secrets Directive: a case of form over substance *John Hull* 6 239
- Experts in the Unified Patent Court *Paul England* 2 44
- Generating value in the soybean chain through royalty collection: an international study (Articles) *Pablo Bergadá, Miguel A. Rapela, Roberto Enriquez, Diego Riso and Juan F. Mendizabal Frers* 5 171
- Henry Carr J jabs patentability in Men B case *Ailsa Carter* 4 131
- Impact of the new EU Nagoya Protocol compliance regime on the cosmetics industry as illustrated by *Sophora Japonica* *Bart van Vooren* 4 142
- Injunctions in pharmaceutical patent cases: the approach of the English courts and the likely impact of the UPC *David Rose and Nina O' Sullivan* 3 111
- Latest news on medicinal product SPCs in Europe *Alice de Pastors* 1 18
- Nanomaterials in the EU regulatory framework on chemical products *Aratz Ramirez de la Piscina* 2 49
- Patentability of medical treatments *Michael Blakeney* 6 224
- Promoting the off-label use of medicines: where to draw the line? *James Killick and Geneva Forwood* 1 3
- UPC Rules of Procedure are agreed. What do they say? *Paul England* 1 8

CASE COMMENTS

- Antimicrobial resistance: a brief review of the O'Neill report *Asawari Churi* 4 162
- Calculation of SPC duration: Case C-471/14 *Seattle Genetics* *Gareth Morgan* 1 31
- Declaratory relief in the English Patents Court *Paul England and Andrew Payne* 3 123
- Genentech*: the Court of Justice of the EU rejects a competition law defence in a patent royalty action *Dr Michele Giannino* 4 165
- GSK and others fined as CMA concludes investigation into paroxetine pay-for-delay settlements *Dervla Broderick* 2 68
- Implications of the TPP agreement on exclusivity for biologics and biosimilars in Australia *Kim O'Connell and Anna Spies* 2 73

- Isolated nucleic acid sequences no longer patentable in Australia: *D'Arcy v Myriad Genetics Inc* *Kim O'Connell and James Ellsmore* 1 25
- Latest case on SPCs: the CJEU rules in favour of chaos *Mike Snodin* 6 248
- Nexus between inspection and enforcement: *R (Roche Registration Ltd) v Secretary of State for Health* *Chris Warburton and John Cooper* 2 63
- Regeneron Pharmaceuticals v Kymab and Novo Nordisk* *Brian Whitehead and Stuart Jackson* 3 119
- Regulatory guidance: the importance of clarity *R (Richmond Pharmacology Ltd) v Health Research Authority* *Chris Warburton* 4 158
- UN leads the way on antimicrobial resistance *Asawari Churi* 6 252
- What's all the buzz about GM insects? UK House of Lords Science and Technology Committee report on GM insects *Helen Cline* 2 76

BOOK REVIEW

- Intellectual property and genetically modified organisms: a convergence in laws (Charles Lawson and Berris Charnley, eds) *Tim Roberts* 1 33

Case List

- Actavis Group PTC EHF and Another v Eli Lilly and Company* [2015] EWHC 3294 (Pat) (16 November 2015) 2 39
- Arrow Generics Limited and Another v Merck & Co, Inc* [2007] EWHC 1900 (Pat) 3 127
- D'Arcy v Myriad Genetics Inc and Another (Australia)* [2015] HCA 35 1 25
- F. Hoffmann-La Roche AG v Accord Healthcare OÜ (CJEU)* (Case C-572/15) 5 October 2016 6 248
- Fujifilm Kyowa Biologics Co., Ltd v Abbvie Biotechnology Ltd* 3 123
- Genentech Inc v Hoechts GmbH et Sanofi-Aventis Deutschland GmbH (CJEU)* (Case C-567/14) ECLI:EU:C:2016:526
- GlaxoSmithKline UK Ltd v Wyeth Holdings LLC* [2016] EWHC 1045 (Ch) 4 131
- Nokia Corporation v InterDigital Technology Corporation* [2004] EWHC 2920 (Pat), [2005] EWCA Civ 624 3 126
- R (Richmond Pharmacology Ltd) v Health Research Authority* [2015] EWHC 2238 (Admin) 4 158
- R (Roche Registration Ltd) v Secretary of State for Health* [2015] EWCA Civ 1311 2 63
- Regeneron Pharma Inc and Bayer Pharma AG v Genentech Inc* [2013] EWCA Civ 93 2 39
- Regeneron Pharmaceuticals Inc v Kymab Limited and Novo Nordisk A/S* [2016] EWHC 87 (Pat) 3 119
- Seattle Genetics (CJEU) Case C-471/14* 6 October 2015 1 31